REFER VENUSREM in my #2 post
Venus Remedies has launched a novel formulation 'ACHNIL' brand of 'Aceclofenac- injection' in India. This novel formulation based on NDDS (Novel Drug Delivery System) technology will fill in the gap of long standing demand for better pain management therapies especially for aged population. It is not only going to reduce the number of pricks but will also drastically reduce the side effects associated with the use of NSAIDs. ACHNIL acts directly by giving instant relief from acute pain and is effective for the next 24 hours against the conventional daily dose of three injections of diclofenac given every 8 hours.
The development of ACHNIL commenced at VMRC and took more than seven years in the successful completion of phase-I, phase-II and phase-III clinical trials and regulatory approvals from DCGI for this product. The marketing team of Venus is fully geared upon all India launch to take, this innovative pain solution drug in most needed Indian market. The Indian market for pain management is approximately Rs 2000 crore which is growing at the rate of 16% - 20% annually and is expected to be of Rs 3500 crore by 2015. Venus is expecting substantial shares in the coming years. ACHNIL ensures immediate burst release action, which gives results with in 4-5 minutes and rest drug is released in controlled manner thereby passing the true benefits of Aceclofenac.
The company made this announcement during the trading hours today, 11 July 2011.
